The AstraZeneca Barcelona Global Hub has been formally recognised as one of the premier foreign investment projects in Europe. Consequently, it secured fourth place in the inaugural Investment Impact Awards.
Presented by fDi Intelligence, a specialist division of the Financial Times group, the award highlights the significant economic and scientific contribution of the pharmaceutical giant’s new facility in the Catalan capital.
Your browser does not support the video tag.Home » AstraZeneca Barcelona Global Hub Named Top European Investment
AstraZeneca Barcelona Global Hub: A Landmark Facility
Located in the iconic Edificio Estel, the AstraZeneca Barcelona Global Hub was inaugurated in November. Therefore, it now serves as a major international centre for biomedical research and innovation. Spanning 30,000 square metres, the facility accommodates nearly 1,600 employees. This cements its status as a critical node in AstraZeneca’s global network.
The project represents a massive financial commitment to the region. In addition, the multinational pharmaceutical company has pledged a total investment of €1.3 billion into the hub through to 2027.
Laura Colón, President of AstraZeneca Spain, noted that the award reinforces the company’s long-term strategy. She stated that the recognition “reaffirms AstraZeneca’s firm and long-term commitment to Catalonia and Spain, and especially to its science and innovation ecosystem.”
Strategic Public-Private Collaboration for the Hub
The distinction from fDi Intelligence also acknowledged the vital role of local institutions in facilitating the project. Acció-the agency for business growth under the Generalitat’s Department of Business and Labour-and the Barcelona City Council were both cited as “key allies” in bringing the hub to fruition.
Miquel Sàmper, the Catalan Minister of Business and Labour, welcomed the accolade as proof of the region’s competitive edge. He argued that the award “demonstrates the enormous appeal of Catalonia when internationally renowned companies seek the best location to grow their projects.”
Similarly, Raquel Gil, Deputy Mayor for Economic Promotion at Barcelona City Council, emphasised the talent factor. She remarked that the arrival of major players like AstraZeneca confirms Barcelona as “a leader in offering talent and a consolidated and reliable option to give scope to activity.”
Catalonia’s Life Sciences Ambitions and the AstraZeneca Hub
The success of the AstraZeneca Barcelona Global Hub aligns with a broader regional strategy to dominate the life sciences sector. Meanwhile, Acció is currently leading a new strategy for attracting foreign investment for the 2026–2030 period, with life sciences identified as a priority vertical.
The regional government has set ambitious targets for this period. It aims to attract over €6 billion in foreign investment and create 45,000 new jobs by 2030. This further establishes Catalonia as a European heavyweight in scientific innovation, building on Catalonia’s strong economic growth.
Get all of the news delivered to your phone via our WhatsApp Broadcast Channel .
